ReviewEuropean cardiology2023
Fulminant Myocarditis: When One Size Does Not Fit All - A Critical Review of the Literature.
Review in European cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Early Cardiac Rehabilitation in Awake Veno-Arterial ECMO for Fulminant Myocarditis: A Case Report.Clinical case reports · 2026Article
- Influenza B Viral Infection Complicated by Acute Fulminant Myocarditis Requiring Mechanical Support: A Case Report.Journal of the Saudi Heart Association · 2026Article
- cfDNA methylation detection as potential liquid biopsy of multiple organ injury in myocarditis patients.Clinical epigenetics · 2025Article
- A Narrative Overview of Fatal Myocarditis in Infant with Focus on Sudden Unexpected Death and Forensic Implications.Journal of clinical medicine · 2025Review
- Editorial: Case reports in thrombosis: 2024.Frontiers in cardiovascular medicine · 2025Article
- Outbreak of Acute Fulminant Myocarditis in Children in Campania Region, Italy: A Case Series.Children (Basel, Switzerland) · 2024Article
- Novel Immunohistochemical and Morphological Approaches in a Retrospective Study of Post-Mortem Myocarditis.Medicina (Kaunas, Lithuania) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fulminant myocarditis, rather than being a distinct form of myocarditis, is instead a peculiar clinical presentation of the disease. The definition of fulminant myocarditis has varied greatly in the last 20 years, leading to conflicting reports on prognosis and treatment strategies, mainly because of varied inclusion criteria in different studies. The main conclusion of this review is that fulminant myocarditis may be due to different histotypes and aetiologies that can be diagnosed only by endomyocardial biopsy and managed by aetiology-directed treatment. This life-threatening presentation requires rapid, targeted management both in the short term (mechanical circulatory support, inotropic and antiarrhythmic treatment and endomyocardial biopsy) and in the long term (including prolonged follow-up). Fulminant presentation has also recently been identified as a risk factor for worsened prognosis, even long after the resolution of the acute phase of myocarditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.